Associations - EGFR T790M

EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	aumolertinib Sensitive: A1 - Approval aumolertinib Sensitive : A1	aumolertinib Sensitive: A1 - Approval aumolertinib Sensitive : A1
EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer	EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1
EGFR T790M	Lung Cancer	EGFR T790M	Lung Cancer	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR T790M	Small Cell Lung Cancer	EGFR T790M	Small Cell Lung Cancer	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	rociletinib Sensitive: C2 – Inclusion Criteria rociletinib Sensitive : C2	rociletinib Sensitive: C2 – Inclusion Criteria rociletinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	ASP8273 Sensitive: C2 – Inclusion Criteria ASP8273 Sensitive : C2	ASP8273 Sensitive: C2 – Inclusion Criteria ASP8273 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	ASK120067 Sensitive: C2 – Inclusion Criteria ASK120067 Sensitive : C2	ASK120067 Sensitive: C2 – Inclusion Criteria ASK120067 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria osimertinib + ramucirumab Sensitive : C2	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria osimertinib + ramucirumab Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	olmutinib Sensitive: C2 – Inclusion Criteria olmutinib Sensitive : C2	olmutinib Sensitive: C2 – Inclusion Criteria olmutinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	firmonertinib Sensitive: C2 – Inclusion Criteria firmonertinib Sensitive : C2	firmonertinib Sensitive: C2 – Inclusion Criteria firmonertinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	abivertinib Sensitive: C2 – Inclusion Criteria abivertinib Sensitive : C2	abivertinib Sensitive: C2 – Inclusion Criteria abivertinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	befotertinib Sensitive: C2 – Inclusion Criteria befotertinib Sensitive : C2	befotertinib Sensitive: C2 – Inclusion Criteria befotertinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	rilertinib Sensitive: C2 – Inclusion Criteria rilertinib Sensitive : C2	rilertinib Sensitive: C2 – Inclusion Criteria rilertinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + anlotinib Sensitive: C2 – Inclusion Criteria osimertinib + anlotinib Sensitive : C2	osimertinib + anlotinib Sensitive: C2 – Inclusion Criteria osimertinib + anlotinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer	EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	bevacizumab + osimertinib Resistant: C3 – Early Trials bevacizumab + osimertinib Resistant : C3	bevacizumab + osimertinib Resistant: C3 – Early Trials bevacizumab + osimertinib Resistant : C3
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3